New drugs for patients with pancreatic cancer

Current Opinion in Oncology

Volumn 14, Issue 6, 2002, Pages 621-627

  Von Hoff, Daniel ^a   Bearss, David ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; C 1994; CAPECITABINE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FISH OIL; FLUOROURACIL; FOLINIC ACID; GASTRIN DERIVATIVE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; ICOSAPENTAENOIC ACID; IRINOTECAN; MARIMASTAT; N ACETYLDINALINE; OCTREOTIDE; OFLOXACIN; OXALIPLATIN; PLEVITREXED; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN G17DT; RUBITECAN; SEOCALCITOL; TEGAFUR; THYMIDYLATE SYNTHASE INHIBITOR; TIPI FARNIB; TIPIFARNIB; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; 9-NITROCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; CANCER VACCINE; DEOXYCYTIDINE; DIPHTHERIA TOXOID; DRUG DERIVATIVE; GASTRIN; GASTRIN IMMUNOGEN;

ADVANCED CANCER; ANEMIA; ARTHRALGIA; BILE DUCT OBSTRUCTION; BLOOD TOXICITY; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; GENE MUTATION; HAND FOOT AND MOUTH DISEASE; HUMAN; HYPOKALEMIA; MALAISE; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STENT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN; HISTORY; PALLIATIVE THERAPY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CANCER VACCINES; DEOXYCYTIDINE; DIPHTHERIA TOXOID; GASTRINS; HISTORY, 16TH CENTURY; HUMANS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036855814     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200211000-00006     Document Type: Review

References (54)

1. Jemal A, Thomas A, Murray T, et al.: Cancer Statistics 2002. Cancer Journal for Clinicians 2002, 52:23-47.
2. Almoguera C, Shibata D, Forrester K, et al.: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
3. Rowinsky E, Windle J, Von Hoff D: Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development. J Clin Oncol 1999, 17:3631-3652.
4. Prendergast G, Oliff A: Drug targeting strategies in cancer therapy. Semin Cancer Biol 2001, 10:443-452.
5. End D, Smets G, Todd A, et al.: Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro. Cancer Res 2001, 61:131-137.
6. Burris IH, Moore M, Anderson J, et al.: Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. J Clin Oncol 1997, 15:2403-2413.
7. Von Hoff D, Mahadevan D, Bearss D: New developments in the Treatment of Patients with Pancreatic Cancer. Clinical Oncology Updates 2001, 4:1-15.
8. Patnaik A, Eckhardt S, Itzbicka E, et al.: A Phase I and Pharmacokinetic (Pk) Study of the Farnesyltransferase Inhibitor, R115777 in Combination with Gemcitabine (Gem) [abstract 5A]. Proc Ann Meet Am Soc Clin Oncol 2000, 19:2a.
9. Van Cutsem E, Karasek P, Oettle H, et al.: Phase III trial comparing gemcitabine plus R115777 (Zarnestra) versus gemcitabine plus placebo in advanced pancreatic cancer (PC) [abstract 517]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:130a.
10. Howard C, Guisbert E, Schaefer J, et al.: In vivo antitumor activity of Cl-994 (N-acetyl-dinaline, GOE 5549) alone and in combination with gemcitabine against LC-12 squamous cell lung carcinoma [abstract 3893]. Proceedings of AACR 90th Annual Meeting 1999, 40:590.
11. Richards D, Waterhouse D, Wagener D, et al.: Randomized double-blind, placebo-controlled phase 2 study of the histone deacetylase inhibitor Cl-994 plus gemcitabine (Cl-994plusG) versus placebo plus gemcitabine (PplusG) in the treatment of patients with advanced pancreatic cancer (APC) [abstract 644]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:162a.
12. Eckel F, Schmelz R, Erdmann J, et al.: Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic cancer [abstract 2286]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:118b.
13. Gilliam A, Watson S, Henwood M, et al.: Use of the tumor marker CA19-9 for monitoring response to immunotherapy for advanced pancreatic cancer [abstract 2981]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:291b.
14. Cohen S, Ho L, Ranganathan S, et al.: Phase II and pharmacodynamic trial of the farnestyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma [abstract 545]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:137a.
15. Macdonald J, Chansky K, Whitehead R, et al.: A phase II study of farnestyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study [abstract 548]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:138a.
16. Okada S, Okusaka T, Ueno H, et al.: A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer (APC) [abstract 682]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:171a.
17. Lapointe R, Letourneau R, Steward W, et al.: Phase 2 study of troxacitabine in chemotherapy naive patients with advanced cancer of the pancreas [abstract 565]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:142a.
18. Smith D, Gallagher N, Garnett S: A phase II/III trial of efficacy and tolerability of ZD9331 vs gemcitabine in pancreatic cancer [abstract 574]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:144a.
19. Evangelos A, Briasoulis A, Pavlidis N, et al.: Phase II study on glufosfamide administered as a 60 minute infusion every 3 weeks in advanced pancreatic cancer [abstract 3713]. Proceedings of AACR 93rd Annual Meeting 2002, 43:748.
20. Halford S, Yip D, Karapetis C, Strickland A, et al.: A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic cancer. Ann Oncol 2001, 12:1399-402.
21. Evans T, Colston K, Lofts F, et al.: A Phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86:680-5.
22. Evans J, Stark A, Johnson C, et al.: A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 2001, 85:1865-1870.
23. Cartwright T, Cohn A, Varkey J, et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20:160-164.
24. Konstadoulakis M, Antonakis P, Tsibloulis BG, et al.: A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2001, 48:417-420.
25. Fernandez-Morales L, Pudadas J, Garcia Y, et al.: Combination of oral tegafur (TF) and levofolinic acid (LA) with gemcitabine (gem) in locally advanced or metastatic pancreatic carcinoma: A pilot study [abstract 2362]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:137b.
26. Tsuji A, Morita S, Horimi T, et al.: A phase II study of 5-FU (CVl) and low-dose consecutive CDDP (LFP) therapy in advanced pancreatic cancer [abstract 628]. Proc Ann Meet Am Soc Clin Oncol 2002, 21.
27. Schneider B, Ganjoo K, Seitz D, et al.: Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer-A Hoosier Oncology Group study [abstract 546]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:137a.
28. Conroy T, Paillot B, Francois E, et al.: Irinotecan (CPT-11 ), oxaliplatin (L-OHP) plus 5-FU/leucovorin (5FU/LV) as first line chemotherapy in patients (pts) with advanced pancreatic adenocarcinoma (APA) [abstract585]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:147a.
29. Cantore M, Rabbi C, Cavazzini G, et al.: Irinotecan and oxaliplatin combination therapy in patients with advanced pretreated pancreatic cancer [abstract 2197]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:96b.
30. Theodossiou C, Rothenberg M, Helm E, et al.; Octreotide LAR and gemcitabine in pancreatic adenocarcinoma: From bench to bedside [abstract 2208]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:96b.
31. Maiello E, Giuliani F, Valerio M, et al.: Oxaliplatin (OHP) and gemcitabine (GEM) combination therapy in advanced pancreatic cancer (APC): Preliminary results of a multicenter study of the Gruppo Oncologico Italia Meridonate (GOIM) [abstract 2236]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:106b.
32. Wiseman C, Kharazi A, Berliner K, et al.: Whole-cell vaccine/GMCSF thrapy in pancreas cancer patients: Strong correlation between longer survival and decrease in serum CA 19-9 [abstract 1873]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:16b.
33. Borner M, Kralidis E, Friess H, et al.: Raliterxed (Tomudex) and gemcitabine: A phase II study in advanced pancreatic cancer [abstract 2206]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:98b.
34. Lutz M, Ducreux M, Wagener T, et al.: Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: A randomized phase II study of the EORTC-GI group [abstract 498]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:125a.
35. Schmidt C, Fahike J, Kettner E, et al.: Phase II multicenter study of gemcitabine and docetaxel in patients with inoperable or metastatic pancreatic cancer [abstract 577]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:145a.
36. Scheithauer W, Schull B, Ulrich-Pur H, et al.: Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma [abstract 500]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:126a.
37. Gonzalez-Baron M, Mei R, Bolanos M, et al.: Phase II study of a fixed-dose infusion of gemcitabine associated to UFT in advanced pancreatic cancer [abstract 601]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:151a.
38. Fine R, Sherman W, Chabot J, et al.: Biochemically synergistic chemotherapy for advanced pancreatic cancer (PC) [abstract 575]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:144a.
39. Iversen P, Yoshihara P, Moulton H, et al.: Active beta-hCG specific immunotherapy in patients with pancreatic cancer [abstract 96]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:25a.
40. Pelzer U, Hempel C, Stieler J, et al.: Oxaliplatin (OXA) in combination with high dose 5-FU (24h/folinic acid (FA) as salvage therapy in patients with gemzar-refractory advanced pancreatic cancer [abstract 684]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:172a.
41. Alberts S, Townley P, Cha S, et al.: Oxaliplatin and gemcitabine for patients with pancreatic adenocarcinoma: A North central Cancer Center Treatment Group (NCCTG) phase II study [abstract 501]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:126a.
42. Kindler H, Dugan W, Hochster H, et al.: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemeterxed/gemcitabine [abstract 499]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:125a.
43. van Laethem J, Van Maele P, Polus M, et al.: Raltitrexed (Tomudex) and gemcitabine (Gemzar) in advanced pancreatic carcinoma: A Belgian muilticenter phase II study [abstract 547]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:137a.
44. Philip P, Zalupski M, El-Rayes B, et al.: Phase II study of gemcitabine, cisplatin and infusional 5-fluorouracil in patients with metastatic pancreatic cancer [abstract 590]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:148a.
45. Rivera F, Garcia-Castano A, Vega-Villegas M, et al.: A phase II study of UFT, gemcitabine and cisplatin (UFTGP) in advanced pancreatic carcinoma (APC) [abstract 687]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:172a.
46. Wein A, Wehler M, Fischer B, et al.: Phase II study with weekly 24-hour infusion (24-hour inf.) of high-dose 5-fluorouracil (5-FU) and gemcitabine (GEM) in metastatic pancreas cancer (UICC IVb): Final results [abstract 620]. Proc Ann Meet Am Soc Clin Oncol 2002, 21:156a.
47. Gansauge F, Ramadani M, Pressmar J, et al.: NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbeck's Arch Surg 2002, 386:570-574.
48. Wagener D, Wils J, Kok T, et al.: Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: An EORTO gastrointestinal tract cancer group trial. Eur J Cancer 2002, 38:648-653.
49. Rocha Lima C, Savarese D, Bruckner H, et al.: Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer. J Clin Oncol 2002, 20:1182-1191.
50. Kozuch P, Grossbard M, Barzdins A, et al.: Irinotecan Combined with Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (G-FLIP) is an Effective and Noncrossresistant Treatment for Chemotherapy Refractory Metastatic Pancreatic Cancer. The Oncologist 2001, 6:488-495.
51. Barber M, Fearon K, Tisdale M, et al.: Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutrition & Cancer 2001, 40:118-124.
52. Halm U, Schiefke, Fleig W, et al.: Ofloxacin and ursodeoxycholic acid versus ursodeoxycholic acid alone to prevent occlusion of biliary stends: A prospective, randomized trial. Endoscopy 2001, 33:491-494.
53. Wong Y, Brams D, Munson L, et al.: Gastric outlet obstruction secondary to pancreatic cancer: Surgical vs endoscopic palliation. Surgical Endoscopy 2002, 16:310-312.
54. Schneider M, Matsuzaki H, Haorah J, et al.: Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001, 120:1263-1270.